文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 自然科学 > 生物学 > Update on hepatitis B virus infection.
侵权投诉

Update on hepatitis B virus infection.

Update on hepatitis B virus infection.

Submit a Manuscript: doc.guandang.net Desk: doc.guandang.net: 10.3748/wjg.v20.i37.13293

© 2014 Baishideng Publishing Group Inc. All rights reserved.

World J Gastroenterol 2014 October 7; 20(37): 13293-13305

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

TOPIC HIGHLIGHT

WJG 20th Anniversary Special Issues (9): Hepatitis B virus

Update on hepatitis B virus infection

Chan Ran You, Sung Won Lee, Jeong Won Jang, Seung Kew Yoon

Chan Ran You, Sung Won Lee, Jeong Won Jang, Seung Kew Yoon, Division of Hepatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 137-701, South Korea

Author contributions: Yoon SK conducted the review and wrote the manuscript; You CR, Lee SW and Jang JW revised the manuscript.

Correspondence to: Seung Kew Yoon, MD, PhD, Professor, Division of Hepatology, Department of Internal Medicine, Col-lege of Medicine, Seoul St. Mary’s Hospital, The Catholic Uni-versity of Korea, #505 Banpodong, Seocho-gu, Seoul 137-701, South Korea. yoonsk@catholic.ac.kr

Telephone: +82-2-22587534 Fax: +82-2-5369559

Received: November 29, 2013 Revised: March 18, 2014 Accepted: April 5, 2014

Published online: October 7, 2014

test for detection of drug resistance still has limitations in identifying the different substitutions present in the same viral genome, the development of a new virologic test to overcome this limitation is necessary. Among the predictive factors associated with response to pegylat-ed interferon (PEG-IFN) therapy, hepatitis B surface antigen quantification is considered to be a surrogate marker for monitoring response to PEG-IFN. Current practice guidelines stress the importance of profound and durable HBV viral suppression in the treatment of CHB patients. To this end, it is essential to choose a potent antiviral drug with a low risk of resistance for initial treatment of CHB to achieve sustained virological response. This review highlights recent advances in the understanding of the immunopathogenesis of HBV and currently available and developing treatment strategies against HBV infection.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Abstract

Chronic infection with hepatitis B virus (HBV) leads to the development of hepatocellular carcinoma and/or chronic liver failure. Despite extensive research, the im-munopathogenesis is not completely understood. Viral persistence and clinical outcomes following HBV infec-tion depend on viral factors and host factors; including genetic factors that determine a host’s immune mecha-nisms. The primary goal of chronic hepatitis B (CHB) treatment is to eradicate HBV or to at least maintain suppression of HBV replication. Despite recent advances in anti-viral agents for chronic HBV infection, complete eradication of the virus has been difficult to achieve. Agents for the treatment of CHB are divided mainly into two groups: immunomodulating agents and antiviral nucleos(t)ide analogues (NAs). Although NAs are safe, effective and easily administered orally, their long-term use poses the risk of drug resistance. Currently, inter-national evidence-based guidelines have been devel-oped to support physicians in managing CHB patients. However, treatment of patients with drug resistance is still challenging, as only a few classes of anti-HBV drugs are available and cross-resistance between drugs can occur. In addition, as the currently available genotypic

Key words: Hepatitis B virus; Chronic hepatitis B; Nucleos(t)ide analogue; Pegylated interferon; Antiviral therapy

Core tip: The primary goal of chronic hepatitis B (CHB) treatment is to eradicate hepatitis B virus (HBV) or to at least maintain suppression of HBV replication. To this end, it is essential to better understand the immuno-pathogenesis of CHB, although it has yet to be further elucidated. More practically, it is of great importance to choose a potent antiviral drug with a low risk of resis-tance for initial treatment of CHB to achieve sustained virological response. This review highlights recent advances in the understanding of the immunopatho-genesis of HBV and currently available and developing treatment strategies for HBV infection.

You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B vi-rus infection. World J Gastroenterol 2014; 20(37): 13293-13305 Available from: URL: doc.guandang.net DOI: doc.guandang.net

Update on hepatitis B virus infection.

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email